News

New Edition of WHO TB Treatment Guidelines

world health organization
World Health Organization

The World Health Organization’s Stop TB Department has published the fourth edition of Treatment of Tuberculosis: Guidelines. The guidelines contain a number of new recommendations, including a call to discontinue regimens based on just two months of rifampicin (2HRZE/6HE). They reinforce prior WHO recommendations for drug susceptibility testing (DST) at the start of therapy for all previously treated patients, and provide guidance for appropriate treatment approaches in the light of advances in laboratory technology and the country’s progress in building laboratory capacity. They also reaffirm recommendations for supervised treatment, as well as the use of fixed-dose combinations of anti-TB drugs and patient kits as further measures for preventing the acquisition of drug resistance.

You can read the report here: http://www.who.int/tb/publications/tb_treatmentguidelines/en/index.html

More News
22 Jul 2024
The National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) has issued a $30.8 million grant to the Preclinical Design and Clinical Translation of TB Regimens (PreDiCTR) consortium , a new consortium co-led by investigators from Weill Cornell Medicine; the...
27 Jun 2024
On May 17, the World Health Organization (WHO) released its updated  Bacterial Priority Pathogens List (BPPL) 2024 and for the first time in its history it included a drug resistant strain of Mycobacterium tuberculosis. Along with three other new families of antibiotic-resistant bacterial pathogens...
19 Mar 2024
For World TB Day 2024, the WGND is spotlighting a monumental achievement in TB drug research and development: the Global TB Drug Pipeline has never been bigger than it is today. The number of drug candidates being clinically evaluated for use in the treatment of adult pulmonary TB has surpassed...